We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
[Qibaipingfei Capsule down-regulate the levels of calcineurin and nuclear factor of activated T-cells isoform c3 (NFATc3) in chronic obstructive pulmonary disease].
Xi Bao Yu Fen Zi Mian Yi Xue za Zhi = Chinese Journal of Cellular and Molecular Immunology 2015 November
OBJECTIVE: To investigate the effect of Qibaipingfei Capsule (QPC) on the expressions of calcineurin (CaN) and nuclear factor of activated T-cells isoform c3 (NFATc3) of rat models with phlegm and blood stasis syndrome of chronic obstructive pulmonary disease (COPD), and to explore the possible mechanism underlying the intervention of QPC in pulmonary vascular remodeling of COPD.
METHODS: Sixty male Sprague-Dawley (SD) rats were randomly divided into a normal group, a model group, a positive group of nifedipine, a high dose group, a middle dose group and a low dose group of QPC. The rat models with phlegm and blood stasis syndrome of COPD were established by compound methods of forced swimming, smoking and hypoxia. Then the pulmonary function and the pathological alterations of pulmonary vessels were observed. Furthermore, the mRNA and protein levels of CaN and NFATc3 in the lung tissues were determined by real-time quantitative PCR and Western blot analysis.
RESULTS: Compared with the normal group, the forced expiratory volume at 0.3 second (FEV0.3), the forced vital capacity (FVC) and FEV0.3/FVC in the model group were significantly reduced, but compared with the model group, the values mentioned above were restored to different extents in the groups of nifedipine and QPC. The lung tissues of the model group showed the thickening of pulmonary vascular wall and the formation of compensating emphysema. The above pathological changes were relieved in all the treatment groups. Compared with the normal group, the expressions of CaN and NFATc3 in the model group were significantly up-regulated in transcription and translation levels. Compared with the model group, these expressions were down-regulated to various degrees in all the treatment groups.
CONCLUSION: QPC can decrease the levels of CaN and NFATc3 in the lung tissues of COPD.
METHODS: Sixty male Sprague-Dawley (SD) rats were randomly divided into a normal group, a model group, a positive group of nifedipine, a high dose group, a middle dose group and a low dose group of QPC. The rat models with phlegm and blood stasis syndrome of COPD were established by compound methods of forced swimming, smoking and hypoxia. Then the pulmonary function and the pathological alterations of pulmonary vessels were observed. Furthermore, the mRNA and protein levels of CaN and NFATc3 in the lung tissues were determined by real-time quantitative PCR and Western blot analysis.
RESULTS: Compared with the normal group, the forced expiratory volume at 0.3 second (FEV0.3), the forced vital capacity (FVC) and FEV0.3/FVC in the model group were significantly reduced, but compared with the model group, the values mentioned above were restored to different extents in the groups of nifedipine and QPC. The lung tissues of the model group showed the thickening of pulmonary vascular wall and the formation of compensating emphysema. The above pathological changes were relieved in all the treatment groups. Compared with the normal group, the expressions of CaN and NFATc3 in the model group were significantly up-regulated in transcription and translation levels. Compared with the model group, these expressions were down-regulated to various degrees in all the treatment groups.
CONCLUSION: QPC can decrease the levels of CaN and NFATc3 in the lung tissues of COPD.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app